Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06384924 · ClinicalTrials.gov registry record

Raman Spectroscopy and Skin Cancer

A clinical trial of Squamous Cell Carcinoma and Skin Cancer, sponsored by Renee Farrell.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT06384924: Recruiting study of Squamous Cell Carcinoma and Skin Cancer, sponsored by Renee Farrell.

NCT06384924 is a study of Squamous Cell Carcinoma and Skin Cancer that is actively recruiting participants, run by Renee Farrell. The registered enrollment target is 20 participants, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06384924, a study of Squamous Cell Carcinoma and Skin Cancer, is actively recruiting participants, sponsored by Renee Farrell.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

The goal of this observational study is to find out if Raman Spectroscopy, a type of imaging, can be used to determine the size of skin cancer tumors. The main question it aims to answer is: -Can Raman Spectroscopy help figure out how far a tumor spreads? This study will take measurements using laser light from an experimental, handheld probe by lightly touching the skin.

Primary Outcome

Collect the Raman spectroscopy data starting from the center of visible lesion moving outward and also contralateral normal skin. Observe the different spectra peak wavelengths and intensities, which correspond to different chemical composition of the tissue. The Raman Spectra has units of wavelength Raman shift (1/centimeter) on the horizontal axis and arbitrary units of intensity on the vertical axis.

Interventions

  • DEVICE Raman Spectroscopy handheld probe (EmVision, FL, USA)
  • DEVICE Raman Spectroscopy laser source (Hubner Photonics Inc, CA, USA)

Study Locations (1)

New York

  • Stony Brook Hospital - Stony Brook

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-02-13
Est. Completion 2027-02-13
Renee Farrell

1 total trials

What NCT06384924 shows while recruiting

NCT06384924 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (81% lower).

The record links to 3 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Raman Spectroscopy handheld probe (EmVision, FL, USA) is the first listed.

NCT06384924 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06384924 about?

NCT06384924 is a clinical study titled "Raman Spectroscopy and Skin Cancer". The goal of this observational study is to find out if Raman Spectroscopy, a type of imaging, can be used to determine the size of skin cancer tumors. The main question it aims to answer is: -Can Raman Spectroscopy help figure out how far a tumor spreads? This study will take measurements using la...

What is the current status of trial NCT06384924?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-02-13. Estimated completion is 2027-02-13.

What conditions does trial NCT06384924 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma, Skin Cancer, Basal Cell Carcinoma.

What interventions are being tested in trial NCT06384924?

The interventions under investigation include: Raman Spectroscopy handheld probe (EmVision, FL, USA) (DEVICE), Raman Spectroscopy laser source (Hubner Photonics Inc, CA, USA) (DEVICE).

Who is sponsoring clinical trial NCT06384924?

This trial is sponsored by Renee Farrell, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06384924 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06384924's enrollment target sits among peer trials

20 40th of 47 higher than 6 of 47 other Squamous Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06384924, the US trial registry maintained by the National Library of Medicine. NCT06384924 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.